Ruxolitinib

Key Product Details

Product Description

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC₅₀ values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (~6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven myeloproliferative neoplasm mouse model. Ruxolitinib has been identified as targeting human host proteins that interact with SARS-CoV-2. The compound can also be used in protocols for the chemical reprogramming of somatic cells to iPSCs. Orally bioavailable.

Phosphate salt (Cat. No. 7048) also available.

Product Specifications for Ruxolitinib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ruxolitinib

The following data is based on the product molecular weight 306.37.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.26 mL	16.32 mL	32.64 mL
5 mM	0.65 mL	3.26 mL	6.53 mL
10 mM	0.33 mL	1.63 mL	3.26 mL
50 mM	0.07 mL	0.33 mL	0.65 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 20 publications citing the usage of this product.

• Guan Chemical reprogramming of human somatic cells to pluripotent stem cells Nature 2022 PMID: 35418683
• Quintás-Cardama Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010 PMID: 20130243
• Gordon A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nature 2020 PMID: 32353859
• Lin Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org.Lett. 2009 PMID: 19385672

Product Documents for Ruxolitinib